【菠萝因子】卡瑞利珠单抗获批,中国首个肝癌免疫疗法来了!( 三 )


2. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–32.
3. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015; 62: 1190–200.
4. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.Clin Cancer Res. 2019 Jan 15;25(2):515-523.
5. Stein S, Pishvaian MJ, Lee MS, Lee K-H, Hernandez S, Kwan A, et al. Safety and clinical activity of 1L atezolizumab tbevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). J Clin Oncol 36:15s, 2018 (suppl; abstr 4074).
6. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389: 56–66.
7. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19: 940–52.
8. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet. 2017 Jun 24;389(10088):2492-2502.
9. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379: 54–63.
_________


推荐阅读